The Application of Real-Time PCR Technique to Detect Rare Cell Clones with Primary T790M Substitution of EGFR Gene in Metastases of Non-small Cell Lung Cancer to Central Nervous System in Chemotherapy Naive Patients
详细信息 查看全文
- 作者：Tomasz Powrózek ; Pawe? Krawczyk ; Bo?ena Jarosz…
- 关键词：Non ; small cell lung cancer ; EGFR gene ; T790M mutation ; Metastases to central nervous system ; EGFR tyrosine kinase inhibitor
- 刊名：Pathology & Oncology Research
- 出版年：2014
- 出版时间：October 2014
- 年：2014
- 卷：20
- 期：4
- 页码：945-951
- 全文大小：547 KB
- 参考文献：1. Zhou W, Ercan B, J?nne PA, Gray NS (2011) Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett 21(2):638-43 CrossRef
2. Ma C, Wei S, Song Y (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 3:10-8
3. Krawczyk P, Mlak R, Powrózek T, Nico? M, Kowalski DM, Wojas-Krawczyk K et al (2012) Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Wspolczesna Onkol 16(5):401-06 CrossRef
4. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366-77 CrossRef
5. Su K-Y, Chen H-Y, Li K-C, Kuo M-L, Yang JC-H, Chan W-K et al (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non–small-cell lung cancer. J Clin Oncol 30:433-40 CrossRef
6. Oh JE, An CH, Yoo NJ, Lee SH (2011) Detection of low-level EGFR T790M mutation in lung cancer tissues. APMIS 119(7):403-11 CrossRef
7. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S et al (2006) Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 12:43-8 CrossRef
8. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T et al (2006) Frequent / EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119(6):1491-494 CrossRef
9. Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY et al (2011) / EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 12(6):380-86 CrossRef
10. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J et al (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non–small cell lung cancer. Cancer Res 66:7854-858 CrossRef
11. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13(5):528-38 CrossRef
12. Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM et al (2013) Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 8(2):229-37 CrossRef
13. Janjigian YY, Groen HJ, Horn L, Smit EF, Fu Y, Wang F et al. (2011) Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 29(suppl): abstr 7525
14. Fujita Y, Suda K, Kimura H, Matsumoto K, Arao T, Nagai T et al (2012) Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 7(11):1640-644 CrossRef - 作者单位：Tomasz Powrózek (1)
Pawe? Krawczyk (1) (6)
Bo?ena Jarosz (2)
Rados?aw Mlak (1)
Kamila Wojas-Krawczyk (1)
Marek Sawicki (3)
Dariusz Stencel (4)
Tomasz Trojanowski (2)
Janusz Milanowski (1) (5)
1. Pneumonology, Oncology and Allergology Department, Medical University of Lublin, Lublin, Poland
6. Immunology and Genetics Laboratory, Pneumonology, Oncology and Allergology Department, Medical University of Lublin, Jaczewskiego 8, 20-954, Lublin, Poland
2. Neurosurgery and Pediatric Neurosurgery Department, Medical University of Lublin, Lublin, Poland
3. Thoracic Surgery Department, Medical University of Lublin, Lublin, Poland
4. Boehringer Ingelheim Poland, Warsaw, Poland
5. Institute of Agricultural Medicine, Lublin, Poland - ISSN：1532-2807
文摘
The time-limited efficacy of reversible EGFR-TKIs in patients with advanced non-small cell lung cancer (NSCLC) with EGFR gene activating mutations is associated with development of treatment resistance after some period of therapy. This resistance predominantly results from secondary mutations located in EGFR gene, especially T790M substitution. There is limited information available concerning the prevalence of primary T790M mutations in patients with metastatic NSCLC tumors before treatment with EGFR-TKIs. The aim of work was to assess the prevalence of de novo T790M mutations in EGFR gene in tissue samples from NSCLC metastatases in central nervous system (CNS) in both chemotherapy and EGFR-TKI naive NSCLC patients. We analyzed DNA samples isolated from paraffin-embedded tissue from CNS metastases for T790M mutations using real-time PCR and TaqMan probe against the T790M mutant sequence. The tissue samples were taken during palliative neurosurgery in 143 NSCLC patients. Amplification of the T790M-specific sequence was detected in 25 patients (17.5?%). The quantity of mutated DNA was less than 1?% in all samples with amplification, and in vast majority (20 patients, 14?% of all samples) it was even less that 0.1?%. In 5 patients (3.5?%) quantity of mutated DNA ranged from 0.1 to 1?% and true positive results of T790M mutation presence in these patients were most possible. Amplification of this sequence was not concurrent with common EGFR mutations and was not associated with sex, smoking status and pathological type of cancer. There is a possibility to detect the primary T790M mutation in brain metastases of NSCLC in EGFR-TKIs na?ve patients.